A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3861-3864

  Torrisi, Rosalba ^a   Orlando, L ^a   Ghisini, R ^a   Veronesi, P ^a,b   Intra, M ^a   Rocca, A ^a   Balduzzi, A ^a   Cardillo, A ^a   Goldhirsch, A ^a   Colleoni, M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; Cyclophosphamide; Docetaxel; Doxorubicin; Preoperative therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; LETROZOLE; PACLITAXEL; TRASTUZUMAB; TRIPTORELIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; TAXOIDS; TREATMENT OUTCOME;

EID: 33750711029     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Wolff AC and Davidson NS: Primary systemic therapy in operable breast cancer. J Clin Oncol 18: 1558-1569, 2000.
2. Bear HD, Anderson S, Brown A, Smith R, Mamounas E, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL and Wolmark N: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21: 4165-4174, 2003.
3. Smith I, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP and Ogston KN: Neoadjuvant chemotherapy in breast cancer: a significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466, 2002.
4. Hutcheon AW, Heys SD, Sarkar TK, Ogston KN, Eremin O, Walker LG and Miller ID: Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res Treat 82: S9 (abstract 11), 2003.
5. Skipper HE: Laboratory models: some historical perspective. Cancer Treat Rep 70: 3-7, 1986.
6. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishaar WJ, Davidson NE, Martino S, Livingstone R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB and Norton L: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431-1439, 2003.
7. Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, Testore F, Brema F, Pronzato P, Cavazzini G, Sertoli MR, Canavese G, Rosso R and Bruzzi P: Dose-dense adjuvant chemotherapy in early breast cancer patients:, results from a randomized trial. J Natl Cancer Inst 97: 1724-1733, 2005.
8. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP and Baloch Z: Pathological response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 180: 297-304, 1995.
9. Bryant J and Day R: Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51: 1372-1383, 1995.
10. Giordano SH: Update on locally advanced breast cancer. The Oncologist 8: 521-530, 2003.
11. Shenkier T, Weir L, Levine M, Olivetto I, Whelan M and Reyno L: Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical Practice Guidelines for the Care and Treatment of Breast Cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ 170: 983-994, 2004.
12. Orlando L, Colleoni M, Curigliano G, Nolè F, Ferretti G, Masci L, Peruzzotti G, Minchella I, Intra M, Veronesi P, Renne G, Viale G and Goldhirsch A: Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen. Anticancer Res 21: 4135-4139, 2001.
13. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nolè F, Peruzzotti G and Goldhirsch A: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10: 6622-6628, 2004.
14. Cooper BW, Radivoyevitch T, Overmoyer BA, Shenk RR, Pham HT, Samuels JR, Parry MP and Silverman P: Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer Breast Cane Res Treat, in press, 2005.
15. Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R and Sledge GW Jr: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17: 3033-3037, 1999.
16. Von Minckwitz G, Raab G, Caputo A, Schutte M, Hilfrich J, Blohmer JU, Gerber B, Costa D, Merkle E, Eidtmann H, Lampe D, Jackisch, du Bois A and Kauffmann M: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23: 2676-2685, 2005.